General Information of Drug (ID: DMF1OUP)

Drug Name
ACE-1334 Drug Info
Indication
Disease Entry ICD 11 Status REF
Systemic sclerosis 4A42 Phase 1 [1]
Cross-matching ID
TTD Drug ID
DMF1OUP

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Discontinued Drug(s)
Investigative Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Pirfenidone DM6VZFQ Idiopathic pulmonary fibrosis CB03.4 Approved [3]
A435 DMJCL7X Aggressive cancer 2A00-2F9Z IND submitted [4]
TG-C DMLCXPD Arthritis FA20 Phase 3 [5]
LY2157299 DMP8HW1 Arteriosclerosis BD40 Phase 2/3 [6]
Disitertide DM2QBDS Macular degeneration 9B78.3 Phase 2 [7]
SRK-181 DM0EWMT Solid tumour/cancer 2A00-2F9Z Phase 1 [8]
ABBV-151 DMIQXDJ Solid tumour/cancer 2A00-2F9Z Phase 1 [9]
Mannose phosphate DM1LM7D Lesion 8A00-8C12 Discontinued in Phase 2 [10]
ART-144 DMEVT4I Osteoarthritis FA00-FA05 Investigative [11]
⏷ Show the Full List of 9 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Transforming growth factor beta 1 (TGFB1) TTR9XHZ TGFB1_HUMAN Antagonist [2]

References

1 ClinicalTrials.gov (NCT04948554) A Phase 1b Randomized, Double-Blind, Placebo-Controlled, Multiple-Ascending Dose Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of ACE-1334 Plus Standard of Care in Participants With Systemic Sclerosis. U.S.National Institutes of Health.
2 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2023. Adis Insight
3 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
4 Clinical pipeline report, company report or official report of Klus Pharma
5 Clinical pipeline report, company report or official report of Tissue Gene, Inc.
6 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
7 Perspectives of TGF-beta inhibition in pancreatic and hepatocellular carcinomas. Oncotarget. 2014 January; 5(1): 78-94.
8 Clinical pipeline report, company report or official report of Scholar Rock.
9 Clinical pipeline report, company report or official report of AbbVie.
10 The mannose-6-phosphate analogue, PXS64, inhibits fibrosis via TGF-beta1 pathway in human lung fibroblasts. Immunol Lett. 2015 Jun;165(2):90-101.
11 Pharmaceutical products of TORREYA partners. December 2011.